Self-Limited Cytomegalovirus Infection During Natalizumab Treatment for Multiple Sclerosis

Natalizumab is indicated as monotherapy for the treatment of relapsing-remitting multiple sclerosis; it prevents outbreaks and delays the progression of physical disability. Here, we report the case of a 30-year-old patient with multiple sclerosis receiving natalizumab as monotherapy who subsequentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Lima, Marina Rodrigues, Farias, Luís Arthur Brasil Gadelha, da Ponte, Maycon Fellipe, de Arruda Furtado, Luís Edmundo Teixeira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SMC Media Srl 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432828/
https://www.ncbi.nlm.nih.gov/pubmed/30931272
http://dx.doi.org/10.12890/2019_001046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432828/
https://www.ncbi.nlm.nih.gov/pubmed/30931272
http://dx.doi.org/10.12890/2019_001046

Ejemplares similares